

D. Eldon Spackman, PhD

University of Calgary
Community Health Sciences
Ph: 403-210-7891
e-mail: eldon.spackman@ucalgary.ca

Education

Doctor of Philosophy, Pharmaceutical Outcomes Research and Policy Program, University of Washington, 2009

- Dissertation topic: Health Economics Research in Alzheimer's Disease

Master of Arts, Health Economics, University of Calgary, 2006

- Thesis topic: Embedding in Contingent Valuation

Bachelor of Arts, Honours in Economics, University of Calgary, 2002

Academic/Teaching Experience

Assistant Professor, University of Calgary, Community Health Sciences, Dec 2015

- Associate Director, Health Technology Assessment Unit
- Co-teach MDCH 663: Decision Analysis in Economic Evaluation (Spring 2016, 2017)
- Co-teach MDCH 662: Economic Evaluation (Winter 2017)

Research Fellow, University of York, Centre for Health Economics, Feb 2010- Dec 2015

Tutor, University of York, 2011-2014

- Postgraduate health economics programme by distance learning
- Workshops in health economics and advanced modelling

Research Assistant, University of Washington and Tufts Medical Center, 2008-2009

Research Assistant, University of Washington, 2007-2008

Teaching Assistant, Health Care and Society, University of Washington, 2006-2007

Teaching Assistant, Biostatistics Quantitative Methods, University of Washington, 2006

Teaching Assistant, Game Theory Economics, University of Calgary, 2003-2004

Research Assistant, University of Calgary, 2002-2004

Academic Awards, Scholarships and Fellowships

Excellence in Integrative Medicine Research Award, 2014

American Foundation for Pharmaceutical Education, 2009-2010

Warren G. Magnuson Scholarship, 2007-2009

Eli Lilly Inc. Pre-doctoral Fellowship, 2005-2006

University of Washington Top Scholar Award, 2005-2006

Grants

Ongoing Grants

1. Title: Estimating the cost-effectiveness threshold for cancer care in Alberta
Funder: CIHR, Lead: Eldon Spackman, Role: Nominated PI, Total Amount: \$93,250 - Amount Received: \$93,250
2. Title: Alberta Laboratory for Precision Health
Funder: Alberta Innovates: Alberta Precision Health Initiative Development Grant, Lead: Tania Bubela, Role: Co-investigator, Total Amount: \$299,000
3. Title: AH Drug Plan Spending
Funder: Alberta Health, Lead: Braden Manns, Role: Co-Principal Investigator, Total Amount: \$132,000 – Amount Received: \$39,000.
4. Title: Early detection to improve outcomes in people with undiagnosed psoriatic arthritis
Funder: NIHR, Lead: Neil McHugh, Role: Co-investigator, Total Amount: £1,992,806 – Amount Received: £55,639
5. Building Capacity and Supporting HTA in British Columbia

Funder: BC Ministry of Health, Lead: Fiona Clement, Role: Co-Investigator, Total Amount: 270,000 – Amount Received: \$140,892.50.

Completed Grants

1. Title: BRIGHT – Bringing Information & Guided Help Together

Funder: NIHR – CCF, Role: Co-investigator, Total Received: £22,000 - Amount Received: £22,000

2. Title: Production of Technology Assessment Reviews for the National Institute for Health Research, Funder: NIHR TAR Programme, Lead: Lesley Stewart, Role: Co-investigator, Total Amount: £5,249,988 - Amount Received: approx. £200,000

3. Title: Decision Support to the Health Technology Evaluation Team

Funder: NICE, Lead: Allan Wailoo, Role: Co-investigator, Total Amount: £1,000,000 – Amount Received: approx. £50,000

Service – University

Students

Supervisor, University of Calgary, Community Health Sciences, MSc, 2016-present

- Student: Nicolas Iragorri

Supervisor, (Joint with Fiona Clement), University of Calgary, Community Health Sciences, MSc, 2016-present

- Student: Mark Hofmeister

Dissertation Advisor, University of Southern Denmark, Centre for Applied Health Services Research, PhD, 2014 – present

- Dissertation: Cost-effectiveness modelling in Alzheimer's disease
- Student: Liza Elizaveta Sopina

Dissertation Advisor, University of York, Department of Economics and Related Studies, MSc Health Economics, 2014

- Dissertation: Methods for estimating QALYs from trial data
- Student: Abualbishr Alshreef

Dissertation Advisor, University of York, Department of Economics and Related Studies, MSc Health Economics, 2013

- Dissertation: Incorporating patient preference into cost-effectiveness analysis
- Student: Daniel John Pollard

Committees

Chair, Graduate Education Specialization Health Economics, University of Calgary, Community Health Sciences, 2016-present

External Examiner, Candidacy Examination Committee, University of Calgary, Community Health Sciences, 2016

- Student: Lesley Soril

Member, Thesis Committee, University of Calgary, Community Health Sciences, 2016-present

- Thesis: Cost-effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors for the Treatment of Elevated Low-density Lipoprotein Cholesterol Levels
- Student: Ziyu Zhang

Member Athena SWAN, University of York, Centre for Health Economics, 2013-present

Chair TEEHTA meetings, University of York, Centre for Health Economics, 2011-present

Chair CHE seminars, University of York, Centre for Health Economics, 2012- 2013

Member, Thesis Committee, University of Washington, PORPP, MSc, 2009-2010

- Thesis: Transition probabilities in Alzheimer's disease with and without intervention
- Student: Lisa Marie Bloudek

Member, University of Washington, PORPP Admissions Committee, 2007-2008

Service – Professional

Associate Editor

BMC Public Health 2010-present

Conference Organizer

Alberta Health Economics Study Group, 2016

Committee Membership

NICE Technology Appraisal Committee 2011-2015

NIHR HS&DR Improving Access to Psychological Therapies in British Sign Language Steering Committee 2014 -2016

HTA School Entry Hearing Study Steering Committee 2012-2015

PPSRU Unit Cost Advisory Group 2011-2015

ISPOR Health Policy Special Interest Group 2010-13

Reviewer for Grants

NIHR Health Services and Delivery Research Programme

NIHR Programme Grants for Applied Research

HTA Clinical Evaluation and Trials

Reviewer for professional journals

NIHR Journals Library

Value in Health

Alzheimer's & Dementia

Pharmacoeconomics

Social Science & Medicine

BMC Pulmonary Medicine

Health Outcomes Research in Medicine

American Journal of Alzheimer's Disease & Other Dementias

Professional affiliations

Member, International Society for Pharmacoeconomics and Outcomes Research, 2006-present

Member, Health Economics Study Group, 2010-2015

Member, Society for Medical Decision Making, 2005, 2010-2011

Member, American Association for the Advancement of Science, 2007-2010

Manuscripts and Presentations

Preparing for Submission

1. [Spackman E](#), Weaver C, Faria R, Soares M. Estimating Markov State Transition Probabilities from Published Kaplan-Meier Survival Curves. Target: Medical Decision Making. July 2017.
2. Sopina E, [Spackman E](#), Sørensen J. Survival and predictors of mortality in Alzheimer's disease: a Danish population study. Target: The Lancet Neurology. June 2017.
3. Han D, Danthurebandara V, Dowsett L, Lorenzetti D, Noseworthy T, Clement F, [Spackman E](#). A Cost-effectiveness Analysis of Newborn Hyperbilirubinemia Screening Strategies. Target: JAMA Pediatrics. July 2017.
4. Walker S, [Spackman E](#), Kazem Rahimi, Sculpher M. Quantifying the health effects of a failure to adhere to clinical guidelines: the case of heart failure based on the National Heart Failure Audit. Target: Open Heart. July 2017.

5. Memedovich KA, Dowsett LE, [Spackman E](#), Saah R, Noseworthy T, Clement F. A Systematic Review on the Adverse Health Effects and Harms Related to Marijuana Use. Target: PLOS Medicine. July 2017.
6. Holitzki H, Saah R, Dowsett L, Ghali S, [Spackman E](#), Noseworthy T, Clement F, on behalf of the HTA Unit. Substance Use Pathways: A Systematic Review of Evidence for the Role of Cannabis as a Gateway Substance.
7. Davis-Unger J, Pajor EA, Schwartzkopf-Genswein K, Marti S, Dorin C, [Spackman E](#), Orsel K. Economic impact of beef cattle lameness in feedlot cattle. July 2017.
8. Tingle B. [Spackman E](#). Do Corporate Fiduciary Duties Matter? Target: University of Toronto Law Journal. 2017.
9. [Spackman E](#). Incorporating Patient Perceptions about Treatment in Cost Effectiveness Analysis. Medical Decision Making. August 2017.
10. Premji S, McDonald SW, McNeil DA, [Spackman E](#). Postpartum Depression Screening in Alberta, Canada: A Cost-Effectiveness Analysis. August 2017.

Submitted

1. [Spackman E](#), Haines-Saah R, Danthurebandara V, Dowsett E, Noseworthy T, Clement F. Marijuana Use and Perceptions of Risk and Harm: A Survey among Canadians in 2016. Submitted: Healthcare Policy. Accepted.
2. [Spackman E](#), Hinde S, Bojke L, Payne K, Sculpher M. Using cost-effectiveness analysis to quantify the value of genomic-based diagnostic tests: recommendations for practice and research. Target: Genetic Testing and Molecular Biomarkers. May 2017.
3. Dowsett L, Clement F, Coward S, Lorenzetti D, Noseworthy T, Sevick L, [Spackman E](#). Effectiveness of Treating Tarlov Cysts: A Systematic Review of Published Literature. Submitted: Clinical Spine Surgery April 2017.
4. Faria R, Soares M, [Spackman E](#), Ahmed H, Brown L, Kaplan R, Emberton M, Sculpher M. Optimising the diagnosis of prostate cancer in the era of multi-parametric magnetic resonance imaging: a cost-effectiveness analysis based on the PROMIS study. European Urology. Jan 2017.
5. Memedovich KA, McCarron T, Dowsett LE, Brooks K, [Spackman E](#), Saah R, Noseworthy T, Clement F. Marketing marijuana: what policy issues exist? Journal of Public Policy and Marketing. May 2017.

Publications

1. Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, Soares M, [Spackman E](#), Rothery C. A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions. Value in Health 2016; Oct;19(6).
2. Hinde S, Wade R, Palmer S, Woolacott N, [Spackman E](#). Apremilast for the treatment of moderate to severe plaque psoriasis: A critique of the evidence. *Pharmacoeconomics*. 2016. Jun;34(6).
3. Corbett M, Soares M, Jhuti G, [Spackman E](#), Sideris E, Moe-Byrne T, Fox D, Marzo-Ortega H, Kay L, Woolacott N, Palmer S. Tumour necrosis factor- α inhibitors for ankylosing spondylitis

and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. *Health Technol Assess.* 2016; Feb;20(9).

4. Dilokthornsakul P, McQueen B, Chaiyakunapruk N, Spackman E, Watanabe JH, Campbell JD. Value of Information in Asia: Concepts, Current Use, and Future Directions. *Value in health Regional Issues.* 2016 May;9.
5. Wade R, Sideris E, Paton F, Rice S, Palmer S, Fox D, Woolacott N, Spackman E. Graduated compression stockings for the prevention of deep-vein thrombosis in postoperative surgical patients: a systematic review and economic model with a value of information analysis. *Health Technol Assess.* 2015 Nov;19(98).
6. McKenna C, Soares M, Claxton K, Bojke L, Griffin S, Palmer S, Spackman E. Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required. *Value in Health.* 2015;18(6).
7. Wade R, Duarte A, Simmonds M, Rodriguez-Lopez R, Duffy S, Woolacott N, Spackman E. The clinical and cost effectiveness of aflibercept in combination with irinotecan and fluorouracil-based therapy (FOLFIRI) for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy: a critique of the evidence. *Pharmacoeconomics.*2015;33(5).
8. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M. Methods for the estimation of the NICE cost-effectiveness threshold. *Health Technol Assess.* 2015;19(14).
9. Spackman E, Richmond S, Sculpher M, Bland MJ, Brealey S, Gabe R, Hopton A, Keding A, Lansdown H, Perren S, Torgerson D, Watt I, MacPherson H. Cost-effectiveness analysis of acupuncture, counselling and usual care in treating patients with depression: the results of the ACUDep trial. *PLOS One.* 26 November 2014.
10. Campbell JD, McQueen RB, Libby AM, Spackman E, Carlson JJ, Briggs A. Cost-Effectiveness Uncertainty Analysis Methods: A Comparison of One-Way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect Information. *Med Decis Making* 2015 Jul;35(5).
11. Hinde S, Spackman E. Bidirectional Citation Searching to Completion: an exploration of literature searching methods. *Pharmacoeconomics.*2015 Jan;33(1).
12. Blakeman T, Blickem C, Kennedy A, Reeves D, Bower P, Gaffney H, Gardner C, Lee V, Jariwala P, Dawson S, Bossabir R, Brooks H, Richardson G, Spackman E, Vassilev I, Chew-Graham C, Rogers A. Effect of information and telephone-guided access to community support for people with chronic kidney disease: randomised controlled trial. *PLOS ONE.* 16 October 2014.
13. Spackman E, Sculpher M, Howard J, Malfroy M, Llewelyn C, Choo L, Hodge R, Johnson T, Rees DC, Fijnvandraat K, Kirby-Allen M, Davies S, Williamson L. Cost effectiveness analysis of pre-operative transfusion in patients with Sickle Cell Disease using evidence from the TAPS trial. *Eur J Haematol.* 2014 Mar;92(3):249-55.
14. Howard J, Malfroy M, Llewelyn C, Choo L, Hodge R, Johnson T, Purohit S, Rees DC, Tillyer L, Walker I, Fijnvandraat K, Kirby-Allen M, Spackman E, Davies SC, Williamson LM. Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS): a randomised controlled multi-centre clinical trial. *The Lancet.* 2013 Mar;16(381):930–938.

15. MacPherson H, Richmond S, Bland MJ, Brealey S, Gabe R, Hopton A, Keding A, Lansdown H, Perren S, Sculpher M, Spackman E, Torgerson D, Watt I. Acupuncture and Counseling for Depression in Primary Care: a Randomized Controlled Trial. *PLOS Medicine*, 2013.
16. Spackman E, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. The validity of dependence as a health outcome measure in Alzheimer disease. *American Journal of Alzheimer's Disease & Other Dementias*. 2013 May; 28(3):245-252.
17. Faria R, Spackman E, Burch J, Corbacho B, Todd D, Pepper N, Woolacott N, Palmer S. Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE Single Technology Appraisal. *Pharmacoeconomics*. 2013 April; 31(7):551:562.
18. Wade R, Spackman E, Corbett MS, Walker SM, Light K, Naik R, Sculpher M & Eastwood AJ. Adjunctive colposcopy technologies for examination of the uterine cervix – DySIS, LuViva Advanced Cervical Scan and Niris Imaging System: a systematic review and economic evaluation. *Health Technol Assess*. 2013 March; 17(8):1-240.
19. Spackman E, Rice S, Norman G, Suh DC, Eastwood A, Palmer S. Trastuzumab for the treatment of HER2 positive metastatic gastric cancer: A NICE single technology assessment. *Pharmacoeconomics*. 2013 March;31(3):185-194.
20. Longworth L, Youn J, Bojke L, Palmer S, Griffin S, Spackman E, Claxton K. When does NICE recommend the use of health technologies within a programme of evidence development? A systematic review of NICE guidance. *Pharmacoeconomics*. 2013 Jan; 31:137-149.
21. Blickem C, Blakeman T, Kennedy A, Bower P, Reeves D, Gardner C, Lee V, Chew-Graham C, Richardson G, Brooks H, Dawson S, Mossabir R, Jariwala P, Swallow A, Kontopantelis E, Gaffney H, Small N, Spackman E, Rogers A. The clinical and cost-effectiveness of the BRinging Information and Guided Help Together (BRIGHT) intervention for the self-management support of people with stage 3 chronic kidney disease in primary care: study protocol for a randomized controlled trial. *Trials*. 2013;14(28).
22. Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. Measuring Alzheimer Disease Progression with Transition Probabilities: Estimates from NACC-UDS. *Current Alzheimer Research* 2012;9(9):1050-1058.
23. Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, Soares M, Spackman E, Youn J. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. *Health Technol Assess*. 2012;16(46).
24. MacPherson H, Richmond S, Bland MJ, Lansdown H, Hopton A, Kang'ombe A, Morley S, Perren S, Spackman E, Spilsbury K, Torgerson D, Watt I. Acupuncture, Counseling and Usual care for Depression (ACU Dep): study protocol for a randomized controlled trial. *Trials*. 2012;12(209).
25. Bojke L, Spackman E, Hinde S, Helliwell P. Capturing all of the costs in NICE appraisals: the impact of inflammatory rheumatic disease on productivity. *Rheumatology* 2012;51(2):210-215.
26. Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. Review and Meta-Analysis of Biomarkers and Diagnostic Imaging in Alzheimer's Disease. *J Alzheimer Dis*. 2011 Jun;26(4).
27. Bloudek LM, Spackman DE, Veenstra DL, Sullivan SD. CDR State Transition Probabilities in Alzheimer's Disease with and without Cholinesterase Inhibitor Intervention in an Observation

Cohort. *J Alzheimers Dis.* 2011 Feb; 24(3):599-607.

28. Norman G, Rice S, Spackman E, Stirk L, Danso-Appiah A, Suh D, Palmer S, Eastwood A. Trastuzumab for the treatment of HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. *Health Technol Assess.* 2011;15(Suppl. 1):33-42.
29. McLaughlin T, Feldman H, Fillit H, Sano M, Schmitt F, Aisen P, et al. "Dependence" as a unifying construct in defining Alzheimer disease severity. *Alzheimer's & Dementia.* 2010 Nov;6(6):482-493.
30. Campbell JD, Spackman DE, Sullivan SD. The Costs and Consequences of Omalizumab in Uncontrolled Asthma from a USA Payer Perspective. *Allergy.* 2010 Feb;65(9):1141-1148.
31. Fleurence R, Spackman DE, Hollenbeak CS. Does the Funding Source Influence the Results in Economic Evaluations? A Case Study in Bisphosphonates for the Treatment of Osteoporosis. *Pharmacoeconomics.* 2010 April;28(4):295-306.
32. Campbell JD, Spackman DE, Sullivan SD. Health economics of asthma: assessing the value of asthma interventions. *Allergy.* 2008 Dec;63(12):1581-92.
33. Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. *Pharmacoeconomics.* 2008;26(11):937-49.
34. Veenstra DL, Spackman DE, Di Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. *Aliment Pharmacol Ther.* 2008 Jun;27(12):1240-52.
35. Spackman DE, Yeates A, Rentz AM, Hutton J. The cost effectiveness of zonisamide as adjunctive therapy in adult partial seizure epilepsy. *J Med Econ* 2007;10(4): 455-473.
36. Campbell JD, Spackman DE, Sullivan SD. Revisiting the cost-effectiveness of omalizumab. *Allergy.* 2007 Dec;62(12):1469.
37. Caro JJ, O'Brien JA, Hollenbeak CS, Spackman E, Ben-Joseph R, Okamoto LJ, et al. Economic Burden and Risk of Cardiovascular Disease and Diabetes in Patients with Different Cardiometabolic Risk Profiles. *Value in Health.* 2007;10(s1):S12-S20.
38. Hollenbeak CS, Spackman DE, Ben-Joseph RH, Okamoto LJ, Luce BR, Schwartz JS, et al. Predicting the Prevalence of Cardiometabolic Risk Factors When Clinical Data Are Limited. *Value in Health.* 2007;10(s1):S4-S11.
39. Hollingworth W, Spackman DE. Emerging methods in economic modeling of imaging costs and outcomes a short report on discrete event simulation. *Acad Radiol.* 2007 Apr;14(4):406-10.
40. Fleurence R, Spackman E. Cost-effectiveness of biologic agents for treatment of autoimmune disorders: structured review of the literature. *J Rheumatol.* 2006 Nov;33(11):2124-31.

Book Chapters

1. Naci H, Spackman E. National Approaches to Comparative Effectiveness Research. *Handbook of Health Services Research.* Springer, 2016.
2. Spackman E. The Significance and International Influence of NICE. *Health Technology Assessment in Japan.* JiHO, 2013.

Presentations

1. Han D, Clement F and Spackman E. Incorporating Patient Perceptions about Treatment in Cost Effectiveness Analysis. Boston, USA. 2017. Poster.
2. Premji S, McDonald SW, McNeil DA, Spackman E. Postpartum Depression Screening in Alberta, Canada: A Cost-Effectiveness Analysis. Boston, USA. 2017. Poster.
3. Davis-Unger J, Pajor E, Schwartzkopf-Genswein K, Marti S, Dorin C, Spackman E, Orsel K. Economic impact of beef cattle lameness in feedlot cattle. UCVM Research Day. Calgary, Canada. 2017. Oral presentation.
4. Spackman E. Indicators of a High Performing Publicly Funded Drug Plan. Alberta Drug Policy Workshop. Edmonton, Canada. 2016. Invited Talk.
5. Spackman E. The Value of Implementing Guidelines for Heart Failure Patients Post-Hospitalization. Alberta Health Services Community of Practice in Health Economics. Online. 2016. Invited Talk.
6. Spackman E. Perceptions and Evidence on the Health Effects of Marijuana Use: A National Survey and Systematic Literature Review. University of Calgary, Calgary, Canada. 2016. Invited Talk.
7. Spackman E. The Value of Cost-Effectiveness Analysis. University of Calgary, Calgary, Canada. 2016. Invited Talk.
8. Spackman E. A Review of Patient Prioritization in Disease-Specific-Treatment Budgets: The Case of Chronic Hepatitis C by Cipriano and Goldhaber-Fiebert. University of Alberta, Edmonton, Canada. 2016. Invited Talk.
9. Spackman E. A Review of Value of Heterogeneity in COPD: Potential Return to Investment from Individualizing Treatments by Zafari. VanHEM. Vancouver, Canada. 2016. Invited Talk.
10. Weaver C, Spackman E. Estimating Decision Model Transition Probabilities from Published Kaplan-Meier Curves. VanHEM. Vancouver, Canada. 2016. Poster.
11. Spackman E. Trends in HTA: Methods and Social Developments. University of Florida, Gainesville, FL, USA. 2016. Invited Talk.
12. Spackman E, Hinde S, Bojke L, Payne K, Sculpher MJ. Establishing The Cost-Effectiveness of Genomic-Based Diagnostic Tests: Are Current Methods Sufficient and Appropriate? ISPOR Milan, Italy. 2015. Poster.
13. Sopina E, Martikainen JA, Spackman E, Sorensen J. Validation of A Markov Model for Economic Evaluation of Screening and Preventive Interventions In Alzheimer's Disease In Denmark. ISPOR Milan, Italy. 2015. Poster.
14. Alshreef A, Spackman E. Methods to Account for Follow-Up Time Differences when Calculating Qalys from Randomised Controlled Trials. ISPOR Milan, Italy. 2015. Poster.
15. Spackman E. Value Based Pricing: The UK experience (Los precios de los medicamentos en base al valor: la experiencia del Reino Unido). University of Granada, Spain. 2014. Invited Talk.

16. Spackman E. Value Based Pricing, Estimating the Cost-Effectiveness Threshold and Determining the Need for Further Evidence. University of British Columbia, Canada 2014. Invited Talk.
17. Spackman E. Methods and Practicalities of Health Care Decision Making in the UK. University of Calgary, Canada 2014. Invited Talk.
18. Spackman E. Off-label comparators in HTA. 4th International Conference Pharmacoeconomics Section of the Pharmaceutical Association of Serbia. 2014. Invited Talk.
19. Spackman E. Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials. Novo Nordisk, Copenhagen 2014. Invited Talk.
20. McQueen RB, Spackman E, Campbell JD. Expected value of perfect information: Active learning through user friendly computations, displays and application discussions. ISPOR Montreal, Canada 2014. Workshop.
21. Spackman E. Health technology assessment: Methods and applications. Abbott Diabetes Care UK 2013. Invited talk.
22. Kusel J, Spackman E, Walker A, Andersson C. Should off-label agents be used as comparators in health technology assessments? ISPOR Dublin 2013. Issue Panel speaker.
23. Spackman E, Walker SM, Garrison L, Akehurst R. The economic evaluation of diagnostics: challenges and methods for assessing value. ISPOR Dublin 2013. Workshop.
24. Spackman E. Beyond Phase III: Bridging the Access Gap and Addressing the Payer Perspective. Conference Breaking Barriers: Maximising Research & Development Opportunities in the UK. 2012. Invited talk.
25. Spackman E. Economic Evaluations in Health and the Role of NICE. University of Bristol 2012. Invited talk.
26. Spackman E. Uncertainty, evidence and irrecoverable costs: informing approval, pricing and research decisions for health technologies. University of Alberta and University of Calgary 2012. Invited talk.
27. Spackman E. Cost-Effectiveness Appraisals: Value base pricing and the threshold in the UK. University of Tokyo 2012. Invited talk.
28. Spackman E, McKenna C, Griffin S, Soares M, Bojke L, Palmer S, Claxton K. Assessing the significance of irrecoverable opportunity costs: implication for reimbursement, pricing and research decisions. HTAi Bilboa 2012. Oral presentation.
29. Griffin S, Spackman E, Soares M, McKenna C, Claxton K. An integrated formal framework for reimbursement, research and pricing deliberation in health technology assessment. ISPOR Berlin 2012. Poster.
30. Campbell JD, McQueen RB, Libby AM, Spackman E, Carlson JJ, Briggs A. Cost-Effectiveness Uncertainty Analysis Methods: A Comparison of One-Way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect Information. ISPOR Berlin 2012. Poster.
31. Spackman E, Griffin S, Fleurence R, Kim E. "Model Busting": Methods and experience in the critical appraisal of cost-effectiveness models submitted to reimbursement agencies. ISPOR Madrid 2011. Workshop.

32. Spackman E, Fleurence R, Kim E, Naci H. Moving towards value based health care in different constituencies, A presentation on behalf of the ISPOR value based health care special interest group. ISPOR Madrid 2011. Workshop.
33. Spackman E. The health economics of preventive medicine: Is an ounce of screening worth a pound (1.15 euro)? EUFEP Krems Austria, 2011. Invited Talk.
34. Sullivan SD, Bloudek L, Spackman DE, Blankenburg M. A Meta-analysis of Biomarkers and Diagnostic Imaging in Alzheimer's Disease. ISPOR Baltimore, US, 2011.
35. Claxton K, Spackman DE, Griffin S, Palmer S, Longworth L, Bojke L, Youn, J. Unifying research and reimbursement decisions: a framework and algorithm for policy choice. HESG 2011.
36. Longworth L, Youn J, Bojke L, Palmer S, Griffin S, Spackman E, Claxton K. When does NICE issue 'Approval with Evidence' recommendations? A review of 'Only In Research' and 'Approval With Research' recommendations in NICE guidance. HESG 2011.
37. Hinde S, Spackman E, Claxton K, Sculpher M. The cost-effectiveness threshold: The results of a novel literature review method. ISPOR Madrid, Spain 2011. Poster.
38. Spackman DE, Bloudek LM, Sullivan SD. The comparative effectiveness of biomarkers for Alzheimer disease: A systematic review and meta-analysis. SMDM 2010. Oral Presentation.
39. Spackman DE, Griffin S, Claxton K. Unifying research and reimbursement decisions: a framework and algorithm for policy choice. SMDM 2010.
40. Bloudek LM, Spackman DE, Sullivan SD. A Comparison of Transitions between MMSE States of Health and Institutionalization among Alzheimer's Disease Patients versus Non-Alzheimer's Disease Patients Using the NACC-UDS Database. ISPOR 2010.
41. Campbell JD, Spackman DE, Swensen A, Sullivan SD. Cost-Effectiveness of Omalizumab in Moderate-to-Severe Asthma from the US Payer Perspective. ATS 2009.
42. McLaughlin T, Neumann PJ, Spackman E, Mucha L, Jones E, Lacey L, Leibman C, Stern Y. Increasing Dependence on Others is Associated with Increased Resource Use in Dementia. AD/PD 2009.
43. McLaughlin TP, Neumann P, Spackman DE, Mucha L, Jones E, Lacey L, Leibman C, Stern Y. Factors Associated with Nursing Home Placement in Alzheimer's Disease. AAN 2009.
44. Spackman DE, Campbell JD. The Impact and Challenges of Including Patient Cost Sharing in Cost-Effectiveness Analyses from the Payer Perspective. ISPOR 2009.
45. Spackman DE, Campbell JD, Sullivan SD. Health Economics of Asthma: Assessing the Value of Asthma Interventions. ISPOR 2008.
46. Fleurence RL, Spackman E. The Cost-Effectiveness of Biologic Agents for the Treatment of Autoimmune Disorders: A Structured Review of the Literature. ISPOR 2006.